Volitionrx limited: outlines broad strategy to become the 'nets company' worldwide through licensing and updates progress of nu.q® nets test adoption

Henderson, nev. , may 7, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, today announces that chief commercial officer, gael forterre, has issued a commercial update on volition's nu.q® nets product.

VNRX Ratings Summary

VNRX Quant Ranking